The $3 Letšoao la Letlole la Bilione la Biotech: Moo Bokhoni ba Sethala sa Peptide bo Kenang ho Potoloho e latelang ea Capital

OrbiMed e hlile e phahamisitse eng, mme letlole la tlhokomelo ea bophelo bo akaretsang le fetola tlhokahalo ea peptide?

Polypeptid Wholesale Peptidyl Transferase Ha ho joalo, bonyane eseng ka ho toba. Letlole ke koloi e akaretsang ea tlhokomelo ea bophelo, mme ha ho letho ka mabitso a phatlalatso a li-peptide, conjugates kapa bokgoni ba tlhahiso. Boholo ke lets'oao; kabo ea lekala ha e senoloe.

The $3 Letšoao la Letlole la Bilione la Biotech: Moo Bokhoni ba Sethala sa Peptide bo Kenang ho Potoloho e latelang ea Capital

Boholo ba letlole la OrbiMed ka koloi, US$bn Boholo ba letlole la OrbiMed ka koloi, US$bn, joalo ka ha e reriloe ho tsoa mohloling o boletsoeng. Boholo ba letlole la OrbiMed ka koloi, US$bn. data ea bar e hlophisitsoeng: 2021: Matsete a poraefete 1.5, Asia Partners 0; 2022: Matsete a poraefete 1.86, Asia Partners 0; 2026: Matsete a poraefete 1.9, Asia Partners 0; 2021 (IV): Matsete a poraefete 0, Asia Partners 0.8; 2023 (V): Matsete a poraefete 0, Asia Partners 0.751; 2026 (VI): Matsete a poraefete 0, Asia Partners 1.Mohloli: BioSpace 2026-10-16. Boholo ba letlole la OrbiMed ka koloi, US$bn 0 0.5 1 1.5 2 Matsete a poraefete Asia Partners 1.5 0 2021 1.86 0 2022 1.9 0 2026 0 0.8 2021 (IV) 0 0.751 2023 (V) 0 1 2026 (VI) Mohloli: BioSpace (2026-10-16)

Motheo oa papiso o tsoa ho mochine oa khatiso oa khoebo ho e-na le ho lokolloa. Setšoantšo sa FierceBiotech e hlalosa Asia Partners VI e le letlole le leholo ka ho fetisisa la Asia la OrbiMed, kgahlanong le $751 milione bakeng sa Asia Partners V le $800 milione bakeng sa Asia Partners IV, mme o re tlhahiso e ncha e fihlile lilemo tse tharo kamora hore likhakanyo tse fetileng li koaloe. Histori ea letlole la BioSpace e beha Private Investments X ho $1.9 limilione tse likete khahlanong le $1.86 limilione tse likete ho 2022 le $1.5 limilione tse likete ho 2021.

Lintlha tsa tokollo tsa tokollo ho AI, "keketseho ea mekhoa e mecha ea kalafo" le ho hlaha ha China e le setsi se matla sa theknoloji ea baeloji., ka phatlalatso. Li-peptide li lula ka har'a "mekhoa e mecha ea kalafo,” empa eo ke ’malo oa rōna, eseng polelo ea k'hamphani. Phello e sebetsang: nka ho nyolla joalo ka lets'oao la khaello ea chelete e ka 'nang ea theola likhakanyo tsa lichelete tsa pele, eseng e le bopaki ba tlhokahalo ea k'hemistri e itseng.

The $3 Letšoao la Letlole la Bilione la Biotech: Moo Bokhoni ba Sethala sa Peptide bo Kenang ho Potoloho e latelang ea Capital

Ke bokhoni bofe ba peptide boo ho leng thata ho bo etsa, le tseo e leng litšebeletso tsa thepa?

Mosebetsi o boima oa tatellano, conjugation, ho ngola le ho kopanya ka mehla ho ka hloka bokhoni bo khethehileng. Ho bokella chelete ha ho bontše hore na ke litšebeletso life tse tla fumana litaelo kapa tse ka fapanyetsanoang; lekola tšebetso e bontšitsoeng bakeng sa morero o reriloeng.

Bopaki ba tatellano e thata ha bo hlaka ka tsela e sa tloaelehang. Ho 2026 Nature Chemistry datha, 49.9% ea 539 tatellano e hlophisitsoeng ea SPPS e bonts'itse ho kopanngoa ha resin (Tamás et al., Nature Chemistry). Liphetho tse tšoanang tsa boithuto bo boletsoeng esale pele ke palo e bolelang ho feta: mehlala e thehiloeng ho tatellano e fihlile ka mokhoa o batlang 58 ho 60% nepahalo, ha shuffled-sequence-sequences lintlha 57.7%, e seng betere hofeta monyetla hodima sete eo. Ka mantsoe a mang, ha o khone ho shebella tatellano ea software mme oa tseba hore na e tla haha.

Bolelele ke ntlha e le 'ngoe ea kotsi ea synthesis, e seng moeli oa ho hloleha ha 50–60 oa bokahohle. Kopa bopaki bo loketseng ba tatellano le sekala, ho kenyelletsa mekhoa e meng ea litsela moo ho loketseng.

Conjugation ke sebaka sa bobeli se tšoarellang, le karolo ea conjugation ea tataiso ea EMA e hlalosa lebaka. E hloka taolo ea peptide e sa lefelloeng ea mahala le mofuta oa mahala oa conjugate moiety, joalo ka PEG ea mahala kapa linker, mme e phekola di-PEGylation, Multi-PEGylation le PEGylation e seng sebakeng se itseng e le mathata a taolo (Tataiso ea peptide ea maiketsetso ea EMA). Tlhahlobo ea tlhahiso ea PDC e hlahlobiloeng ke lithaka e eketsa hore litekanyetso tse tsitsitseng tsa lithethefatsi-to-peptide tse nang le meputso e kotsi haholo li phahamisa palo ea mehato le moroalo oa QC. (Parang et al., Moralo oa Lithethefatsi, Nts'etsopele le Phekolo). Morekisi ea thathamisang litšebeletso tsa conjugation ea peptide e le ntho ea menu ha a hlalose mosebetsi oo.

Hobaneng botebo ba tlhahlobo bo fetoha moat o tšoarellang ha mananeo a ntse a tsoela pele?

Hobane sebaka sa taolo se ile sa falla, 'me e ile ea leba taolong ea ho se hloeke ka mokhoa o ikhethileng oa peptide ho fapana le molek'hule e nyane Synthesis Peptide mefokolo. Botebo ba tlhahlobo ke bona bo lumellang molekane hore a lule a hlahisa data e ka sirelelitsoeng ka mor'a phetoho eo.

Tataiso ea EMA e qalileng ho sebetsa ka Phuptjane 2026 e beha menyako: litšila tse amanang le peptide li tlalehiloe ka holimo 0.1%, e boletsoeng ka holimo 0.5% mme a tshwaneleha ka hodimo 1.0%, 'me meeli e tšoanang e sebetsa ho lihlahisoa tse felileng (Tataiso ea peptide ea maiketsetso ea EMA). Boemo ba tataiso mabapi le lihlopha tsa litšila tse arohaneng bo sebetsa ka mokhoa o tšoanang: sehlopha pele- 'me litlhōrō tsa ka morao-rao ha li khothalletsoe 'me li amoheleha feela maemong a loketseng.

Lintho tse peli lia latela. Ea pele, molao-motheo o akaretsang oa ICH Q6B oa hore bohloeki bo itšetlehile ka mokhoa o ntse o le teng, 'me Q6B ha e kenyeletse ka ho hlaka li-peptide tsa maiketsetso ho tloha sebakeng sa eona (Ke Q6B). Bohloeki ke palo e hlahisoang ke mokhoa, eseng thepa ea vial. Ea bobeli, lehlakore la US le tsamaile ka tsela e tšoanang: FDA ea July 2026 tlhabollo ea tataiso ea eona ea generic peptide e phatlalalitsoeng 17 litataiso tse ntlafalitsoeng tse mabapi le sehlahisoa tse koahelang menyako ea ho se hloeke, sebopeho sa boemo bo holimo le ts'ebetso ea baeloji, mme setsi se ile sa hula Motšeanong oa sona 2021 tataiso kaha ha e sa bonahatsa monahano oa morao-rao oa saense (U.S. FDA). Peptide Sales

Scalable peptide analytics ka hona e bolela ntho e itseng: mekhoa ea orthogonal, phetiso e ngodiloeng, le litekanyetso tsa litšupiso tseo boleng ba tsona bo abetsoeng bo ka latelloang. Kabelo ea boleng bo tloaelehileng ba USP ke ts'ebetso ea mehato e 'meli, boima bo leka-lekana holim'a thepa e ngata ebe e tlatselletsa tlhahlobo ea HPLC ho vial ea lyophilised, hantle hobane maemo a fanoeng hampe a lebisa ho litekanyetso tse fosahetseng (McCarthy et al., Lipatlisiso tsa Meriana). Botsa molekane hore na litekanyetso tsa bona li abetsoe joang pele u amohela palo ea bohloeki.

E etsa eng $1 Kabelo ea libilione tsa Asia e bolela qeto ea ho fumana moeta-pele oa CMC?

Taba e potolohileng taba ke ea sebele. Li-biotech tsa ntlo-kholo ea Chaena li ikarabella 58% ea boleng bohle ba li-license-deal in 2026 ho intša kgahlanong le 26% bakeng sa lik'hamphani tsa US, ho tloha ho a 14% ho 48% arola ka hare 2023, ka BioSpace, ho qotsa data ea Locust Walk. Manane a li-portfolio a hajoale a OrbiMed 22 Lik'hamphani tsa Asia biopharma (FierceBiotech). Tšoara palo ea laesense joalo ka tataiso: e tsoa ho feme ea likeletso tsa khoebo e ruang molemo tlalehong ea ho tšela moeli.

Bakeng sa qeto ea hau ea ho fumana chelete, lintlha tse sebetsang ke litokomane le matla a ho laola. Kopa lintlha tse ikhethileng tse ngata tseo u ka li hlokang lapeng, netefatsa hore na sebaka se etsang mohato ofe, 'me u fumane esale pele hore na mekhoa ea tlhahlobo e fetisetsa laboratoring ea hau. Kotsi ea maano mabapi le phepelo e thehiloeng China e ntse e phela, sehlooho se sa rarolloang; re ne re ke ke ra theha moralo oa ho fumana sephetho holim'a sephetho sa molao se e-so rarolloe.

Ke bolela joang boleng bo tšoarellang ba sethala ho tsoa ho buzz-cycle buzz ha ke lekola molekane oa peptide?

Kopo ea bokhoni ba bohlokoa e tšehetsoa ke ts'ebetso e nepahetseng le bopaki ba tlhahlobo tlas'a mekhoa e nepahetseng ea morero. Litokomane tsa Lota feela ha li bolele esale pele hore na bokhoni ba khoebo bo tla lula bo tšoarella khoebong.

Ha ho na sekhahla sa katleho sa pele se phatlalalitsoeng bakeng sa tatellano e thata, ’me re ne re tla belaela ka mang kapa mang ea ka qotsang e le ’ngoe. Katleho e itšetlehile ka tatellano, sekala le bohloeki bo kgaohileng, kahoo peresente e le 'ngoe ha e bapisoe ho pholletsa le mananeo. Ho e-na le hoo, botsa mabaka a ka sehloohong.

Mona ke sebaka seo MOL Changes e sebetsang ho sona: sehlopha sa rona se sebetsa ka thata-mohato, mokelikeli-mohato, hybrid le inverse solid-phase synthesis hammoho le ho belisoa ha likokoana-hloko, e sebetsana le li-peptide tsa cyclic le glycopeptides, hape e fana ka biotinylation le fluorescent labeling, le HPLC, MOF, pH, dikahare, tlhahlobo ea endotoxin le sterility e le karolo ea sephutheloana sa tokollo. Re hlalosa tlhahiso e le e akaretsang lisebelisoa tsa sehlopha sa lipatlisiso ka tatellano e telele ho fapana le ho qotsa bolelele bo le bong, hobane siling e nepahetseng e itšetlehile ka tatellano. Haeba u hlahloba molekane, botsa mohlahlobuwa e mong le e mong dipotso tse ka hodimo mme o bapise dikarabo, eseng libukana.

Rekoto ea tlhahiso e bontša eng ka lik'hemik'hale khahlanong le litsela tse kopanyang?

Khetho ea litsela ke qeto e ikhethileng ea boenjiniere, 'me tlhahlobo e hatisitsoeng ea likhetho tsa tlhahiso ka morao ho lithethefatsi tsa blockbuster peptide e e tšoara ka tsela eo ho fapana le khetho ea kamehla. Eptides Supplier Kemiso ea lik'hemik'hale e laola moo molek'hule e leng khutšoanyane ka ho lekaneng 'me ho hlokahala liphetoho; litsela tse kopanyang li kena moo bolelele le menahano e etsang hore kopano ea lik'hemik'hale e se ke ea sebetsa.

Moeli oa taolo o bohlokoa ho tseba hobane o etsa qeto ea hore na ke tataiso efe e laolang faele ea hau. Tataiso ea EMA e sebetsa ho li-peptide tsa maiketsetso 'me ha e sebetse ho lihlahisoa tsa baeloji le tsa biotechnological tse entsoeng ka mahlale a recombinant. (Tataiso ea peptide ea maiketsetso ea EMA). Li-peptide tsa semi-synthetic le tse kopanyang li hlaha ho FDA's 2026 litlhahlobo tsa tataiso e le mekhahlelo e fapaneng ea tlhahiso (U.S. FDA). Ka hona, khetho ea hau ea tsela e etsa qeto ea litebello tsa hau tsa tlhahlobo, eseng feela sebopeho sa litšenyehelo tsa hau.

Lipotso Tse Botsoang Khafetsa

Na OrbiMed e phahamisa ho bolela hore bokhoni ba CDMO ba peptide bo tla hola?

Eseng ka boyona. Taelo e boletsoeng ea tokollo e akaretsa biopharmaceuticals, lisebelisoa tsa bongaka, tlhahlobo le lits'ebeletso tsa tlhokomelo ea bophelo tse nolofalitsoeng ke thekenoloji, le mabitso ha ho matsete a tlhahiso (OrbiMed). Likhamphani tse fihlang ho li-peptide li tla tlameha ho tla ka liqeto tsa kabo ea li-portfolio tse sa hlahisoang. Moralo oa bokhoni mabapi le litumellano tsa phepelo tse saenneng, eseng liphatlalatsong tsa letlole. Fektheri ea Eptides

Ke menyako efe ea ho se hloeke eo ke lokelang ho tšoara mofani oa peptide ho eona?

Bakeng sa faele ea EU, sebelisa litekanyo tsa EMA: tlaleha ka holimo 0.1%, tsebahatsa ka holimo 0.5%, tšoaneleha ka holimo 1.0%, se sebedisoang ho sehlahiswa se phethiloeng mmoho le ntho ya moriana (Tataiso ea peptide ea maiketsetso ea EMA). Bakeng sa faele ea generic ea US, lekola tataiso ea hajoale mabapi le sehlahisoa bakeng sa sehlahisoa sa hau sa litšupiso, ho tloha ka Phupu 2026 lintlafatso li fetotse likhothaletso tse 'maloa.

Litokomane tsa molekane oa ka ea ntseng a le teng li tšesaane. Na mekhoa e ka fetisetsoa bohareng ba lenaneo?

Hangata ho joalo, empa phetiso ka boyona ke kotsi, eseng moo ho yang teng. Kopa lifaele tsa mokhoa oa pele, sephutheloana sa netefatso le lirekoto tsa likabelo tse tloaelehileng pele o itlama. Molekane ea sa khoneng ho hlahisa tseo o u bolella ho hong ka hore na data e entsoe joang.

Qetello

The $3 bilione ke sesupo sa khaello ea chelete, 'me ho hloka chelete ha ho etse hore bokhoni bo tšoarelle. Se etsang hore bokhoni ba sethala sa peptide bo tšoarelle ke bokhoni ba ho hlahisa data e sirelelitsoeng ka tatellano e thata le li-conjugate tse laoloang., tlas'a menyako ea litšila e neng e tiisitsoe 2026 le litebello tsa tlhahlobo tseo balaoli ba Europe le US ba li hlahisitseng.

Keletso ea rona ke ho emisa ho lekola balekane ka bophara ba lethathamo la likhakanyo mme ba qale ho ba lekola ka bopaki: tatellano e thata e bapisoang, mokgoa o rehelletsoeng bakeng sa taolo ya mahala-linker, tekanyetso e ka lateloang, le nalane e netefalitsoeng ea ntlafatso. Haeba molekane a sa khone ho araba lipotso tseo tse 'nè ka lirekoto tse tobileng haholo, karolo e setseng ha e na taba.

Buisana le setsebi sa tekheniki mabapi le tatellano e thata kapa lenaneo la ho eketsa, mme o tlise tatelano eo o tshwenyehileng ka yona.

Tsebiso: Liphetoho tsa MOL li fana ka motsoako oa peptide o tloaelehileng, phetoho, lits'ebeletso tsa ho ngola le ho etsa tlhahlobo ea tlhahlobo. Sengoliloeng sena se ngotsoe ke sehlopha sa rona bakeng sa babali ba hlahlobang balekane ba peptide mme ha se boeletsi ba taolo..

Phatlalatso ea mohatisi: MOL Changes e fana ka litšebeletso tsa peptide mme e na le thahasello ea khoebo sehloohong sena. Mekhahlelo ea litšebeletso le lipolelo tsa bokhoni ke likopo tsa bafani ba thepa; ho fumaneha le ts'ebetso bakeng sa moaho o itseng o hloka bopaki bo ikhethileng ba projeke.

Miao He

Miao He

Setsebi sa Lipatlisiso ho Lits'ebetso tsa Phano Tsebo ea Konokono: Phano ea peptide ea molomo, lipid nanoparticle (LNP) qoelisoa, li-peptide tse kenang liseleng (CPPs), le litlatsetso tse sa khaotseng.

Profile: Mathata a mantlha a ho hlahisa litlhare tsa peptide ke tsa bophelo ba bona bo bokhuts'oane le bothata ba tsamaiso ea molomo, mme Miao He ke setsebi se ka sehloohong sa ho rarolla mathata ana. O na le boiphihlelo bo bongata lefapheng la litsamaiso tsa phepelo ea peptide. Hajoale o tsepamisitse maikutlo ho nts'etsopele ea li-permeation enhancers le li-nanospheres ho ntlafatsa haholo bioavailability ea li-peptide..

'Nete e hlahlobiloe & Litaelo tsa Bahlophisi
E hlahlojoa ke: Litsebi tsa Litaba
Arolelana sehlooho sena
Lehae Batla Whatsapp Litšebeletso Sehlahisoa